Novo Nordisk on problems at contract manufacturer: "They need time"

Further delays are expected before demand for obesity drug Wegovy can be met.

Photo: Novo Nordisk / PR

Obesity drug Wegovy is once again facing a setback on the US market, this time due to a contract manufacturer.

"We are confident that they know what they are doing, but they need time," Executive Vice President for Product Supply, Quality and IT Henrik Wulff says.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs